Novo Nordisk issues profit warning as competition — legal and otherwise — hits Wegovy, Ozempic

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.

Previous Article

SoFi’s stock rises as earnings bring surging loan growth and a number of records

Next Article

Manhattan Skyscraper Gunman Kills Four, Misses NFL Target In Botched Attack 

Write a Comment

Leave a Comment

Your email address will not be published. Required fields are marked *

Subscribe to our Newsletter

Subscribe to our email newsletter to get the latest posts delivered right to your email.
Pure inspiration, zero spam ✨